Table 1.

Clinical studies on Bifidobacterium infantis

Reference	No of participants*	Main results
28	80	Safe consumption and good tolerance of B. infantis; stools significantly fewer and better formed.
29	66	Significant changes to faecal microbiome composition; colonisation with B. infantis; higher abundance of faecal short chain fatty acids; lower stool pH.
30	40	Lower faecal calprotectin levels; lower enteric inflammation.

*Participants in total, meaning the group of children B. infantis fed and the group placebo fed (for all: treatment from day 7 on, dose 1.8–2.8×10¹⁰ colony forming units), all participants were breastfed infants.